A nonprofit that often puts drug makers on edge with reports about the value of medicines may become still more controversial with plans to sound off about “unjustified price increases.”

The Institute for Clinical and Economic Review, which has become influential as a sort of cost-effectiveness watchdog for the pharmaceutical industry, expects to issue an annual report on price hikes thanks to a fresh round of backing from the Laura and John Arnold Foundation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy